Valvular heart disease

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024
Diuretic, Ultrafiltration, Hospital, Section, Artificial intelligence, Randomized controlled trial, Mount Sinai Health System, Quality of life, Acute decompensated heart failure, Hierarchy, Aquapheresis, Valvular heart disease, Risk, Heart failure, Arrhythmia, AUF, ALD, History, Yale School of Medicine, Patient, HF, Machine learning, Cerebrovascular disease, THT, Mortality, Roflumilast, Pharmaceutical industry

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

First Coast Cardiovascular Institute and CardioHealth Partner to Advance Cardiovascular Care for Northeast Florida Residents

Retrieved on: 
Monday, January 29, 2024
Electrophysiology, Valvular heart disease, Patient, Cardiology, Hypertension, Trust, Health, Partnership, Atrial fibrillation, History, Echocardiography, FACC, FCCI, Amputation, Heart, Cardiovascular disease

JACKSONVILLE, Fla., Jan. 29, 2024 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute, a Cardiovascular Logistics partner practice that offers cardiovascular medicine, sleep medicine, pulmonology, and amputation prevention to residents in Northeast Florida and Southern Georgia, has joined forces with CardioHealth, a Jacksonville-based cardiovascular practice that specializes in delivering exceptional care to patients with hypertension, congestive heart failure, atrial fibrillation, and valvular heart disease. Together, they aim to advance cardiovascular care across Northeast Florida.

Key Points: 
  • Together, they aim to advance cardiovascular care across Northeast Florida.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "This collaboration between First Coast Cardiovascular Institute and CardioHealth marks a significant milestone for both practices," said David Konur, CEO of Cardiovascular Logistics.

New State-of-the-Art Hybrid Operating Room Unveiled at MarinHealth Medical Center

Retrieved on: 
Tuesday, December 5, 2023
Health, Hospitals, Surgery, Practice Management, Health Technology, General Health, Cardiology, Radiology, Medicine, Radiation, Ventricular septal defect, Aneurysm, Surgeon, Patient, Coronary artery disease, Hybrid, Valvular heart disease, Physician, Injury, Environment, Life, Medical imaging, Nursing, MD

Today, MarinHealth Medical Center unveiled its new hybrid operating room, a surgical suite that combines the best tools of a traditional operating setting with advanced imaging technology.

Key Points: 
  • Today, MarinHealth Medical Center unveiled its new hybrid operating room, a surgical suite that combines the best tools of a traditional operating setting with advanced imaging technology.
  • With MarinHealth’s new hybrid operating room, Haynes Cardiovascular Institute interventional specialists and surgeons can perform open surgeries and minimally invasive procedures in the same setting.
  • In addition, the hybrid operating room can also be effectively utilized for handling traumatic injuries in both orthopedic and emergency care situations.
  • To learn more about the Hybrid OR at MarinHealth Medical Center, visit MyMarinHealth.org/HybridOR .

Breakthrough Clinical Data: Eko Health's AI Significantly Improves Heart Disease Detection in Primary Care

Retrieved on: 
Monday, November 13, 2023
Principal, Stethoscope, Eko, VHD, Physician, Disease, Mass, Learning, Patient, Heart, FDA, Heart failure, Stroke, Auscultation, Death, Valvular heart disease, Health, American Heart Association, Medical device, AI

EMERYVILLE, Calif., Nov. 13, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions. This data demonstrated the real-world clinical efficacy of Eko's AI-enabled SENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease. Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65. VHD can lead to heart failure, stroke, and death, and if left undetected and untreated, can progress from moderate to severe within one year. Unfortunately, symptoms of VHD are frequently nonspecific, and more than half of patients with moderate to severe disease are asymptomatic, making VHD challenging to detect with conventional medical practice.

Key Points: 
  • EMERYVILLE, Calif., Nov. 13, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions.
  • This data demonstrated the real-world clinical efficacy of Eko's AI-enabled S ENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease.
  • Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65.
  • These results suggest that using Eko's AI-enabled technology in primary care may significantly increase earlier VHD discovery, facilitate appropriate patient care, and improve outcomes.

Agamon Health enters into know-how agreement with Mayo Clinic to close cardiology care gaps with generative AI

Retrieved on: 
Tuesday, November 7, 2023
Valvular heart disease, Physician, Synthetic media, Health, Generative, Cardiology, Interview, Transesophageal echocardiogram, Hospital, Patient, Death, Heart failure, Mayo Clinic, Medical device

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Agamon Health is a healthcare technology company that uses Generative AI and workflow automation to close gaps in patient care. In collaboration with Mayo Clinic through a know-how agreement, Agamon Health aims to extend its offering to cardiology.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Agamon Health is a healthcare technology company that uses Generative AI and workflow automation to close gaps in patient care.
  • In collaboration with Mayo Clinic through a know-how agreement, Agamon Health aims to extend its offering to cardiology.
  • Agamon Health is collaborating with Mayo Clinic to leverage its expertise in Generative AI and workflow automation to enhance patient adherence to follow-up in cardiology.
  • Care gaps in cardiology are a major concern and Agamon Health has technology with the potential to address them - Generative AI combined with workflow automation to reduce the need for manual workflows.

Eko Health Announces Large-Scale Deployment of AI Heart Disease Detection Technology

Retrieved on: 
Monday, November 6, 2023
Patient, FDA, Gold, United Kingdom, Heart failure, ECG, Heart, Eko, Atrial fibrillation, Imperial College Healthcare NHS Trust, UKCA, Ventricular fibrillation, Learning, National Institute for Health and Care Research, NIHR, Trust, Valvular heart disease, Machine learning, U.S. FDA, Imperial College London, HF, Algorithm, Diagnosis, VHD, GP, Medical device, Medical imaging, Cardiology, AI

EMERYVILLE, Calif. , Nov. 6, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today announced the regulatory approval (UKCA marking) and frontline deployment of the company's AI-enabled technology in the United Kingdom (UK). TRICORDER, a National Institute for Health and Care Research (NIHR) funded implementation program led by researchers at Imperial College London, will deploy Eko's AI-enabled technology (marketed in the U.S. as SENSORA™) to primary care practices across the UK. This novel implementation will assist clinicians in their evaluation of heart failure (HF), valvular heart disease (VHD), and atrial fibrillation (AFib), ultimately serving as an AI-enabled clinical decision support tool for echocardiogram referrals.   

Key Points: 
  • Imperial College London and UK NHS initiates TRICORDER program in primary care across the United Kingdom, targeting Heart Failure, Valvular Heart Disease, and Atrial Fibrillation
    EMERYVILLE, Calif. , Nov. 6, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today announced the regulatory approval (UKCA marking) and frontline deployment of the company's AI-enabled technology in the United Kingdom (UK).
  • Eko Health's AI-enabled technology has received UKCA markings and is being deployed in 100 UK primary care practices.
  • This novel deployment can potentially improve heart disease outcomes for millions of people in communities across the UK.
  • "This deployment around the UK of our AI-enabled heart disease detection technology demonstrates the need for accurate and early heart disease detection," said Connor Landgraf, Co-founder and CEO of Eko Health.

Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans

Retrieved on: 
Wednesday, October 18, 2023
Cardiology, Health, Supermarket, General Health, Specialty, Seniors, Pharmaceutical, Convenience Store, Retail, Consumer, Clinical Trials, Research, Ageing, Incidence, CRF, Prevalence, Multimedia, Clinical trial, Valvular heart disease, Partnership, Master of Science, Patient, VHD, Diagnosis, Pharmaceutical industry, MD, Walgreens

View the full release here: https://www.businesswire.com/news/home/20231018497392/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018497392/en/
    Walgreens is collaborating with the Cardiovascular Research Foundation (CRF) to advance the PREVUE-VALVE clinical trial for valvular heart disease treatments.
  • “The aging population has led to a surge in the incidence and prevalence of valvular heart disease in the United States.
  • Unfortunately, many patients with valvular heart disease remain untreated or receive treatment later than recommended due to various barriers.
  • The PREVUE-VALVE study is currently underway, with topline results expected in 2025, making a significant step forward in the fight against valvular heart disease.

Hawthorne Effect Announces Monumental Diversity in Patient Recruitment Data for Valvular Heart Disease Study

Retrieved on: 
Tuesday, October 10, 2023
FDA, CRF, SAN, VHD, Valvular heart disease, Clinical trial, Patient, Prevalence, Pharmaceutical industry

SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Hawthorne Effect, a complete clinical trials solution, today announced interim recruitment results for the PREVUE-VALVE study, a clinical research study led by the Cardiovascular Research Foundation (CRF), that aims to quantify the prevalence of valvular heart disease (VHD). To date, Hawthorne Effect has successfully recruited over 1,000 patients in 48 states plus Hawaii. Patient recruitment also exceeded industry averages according to findings from the Association of Clinical Research Professionals for the below patient demographics, setting a new standard for inclusiveness:

Key Points: 
  • SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Hawthorne Effect , a complete clinical trials solution, today announced interim recruitment results for the PREVUE-VALVE study , a clinical research study led by the Cardiovascular Research Foundation (CRF), that aims to quantify the prevalence of valvular heart disease (VHD).
  • To date, Hawthorne Effect has successfully recruited over 1,000 patients in 48 states plus Hawaii.
  • Hawthorne Effect has accomplished these goals by building a platform that prioritizes inclusive patient recruitment and accessible trial execution.
  • "We have overcome decades-long challenges in clinical research with the PREVUE-VALVE study," said Jodi Akin, founder and CEO of Hawthorne Effect.

Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software

Retrieved on: 
Wednesday, September 13, 2023
Technology, Clinical Trials, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, PW, Heart, Duke University, CE, Partnership, Society, CW, American Society of Echocardiography, Health policy, Graduate Medical School Admissions Test, Heart failure, Anesthesiology, Echocardiography, Deep learning, Nasiriyah Heart Center, Splenic infarction, Associate, 2D, Duke University School of Medicine, Ischemia, Patient, Valvular heart disease, Algorithm, Artificial intelligence, Diagnosis, Cardiomyopathy, Duke University Health System, FDA, Pulmonary hypertension, Duke–NUS Medical School, Syndrome, Medtech, Medical device, Medical imaging, Doppler effect, Medicine

In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.

Key Points: 
  • In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.
  • Even at the most well-resourced setting, the process of acquiring, measuring, and analyzing the images is time-consuming and labor-intensive, making the routine echocardiography application unsustainable.
  • Advances in deep learning have made automated analysis of medical images possible,” said Dr. Manesh Patel, Chief of Cardiology and Co-Director of the Heart Center at Duke University Health System.
  • This covers the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.

Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US

Retrieved on: 
Wednesday, August 23, 2023
University of Virginia Health System, University, TR, Food and Drug Administration, Cardiopulmonary bypass, Risk, Valvular heart disease, EFS, Principal, Food, Medical device, Trisol, MD

YOKNEAM, Israel, Aug. 23, 2023 /PRNewswire/ -- The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD.

Key Points: 
  • We were able to abolish the patient's valvular heart disease via a minimally invasive procedure without the need for cardiopulmonary bypass.
  • Trisol patented valve features a distinctive design, that sets it apart from other tricuspid valves technologies.
  • Trisol valve is comprised of a single leaflet, the leaflet is affixed by 2 commissures enabling it to function as a bi-leaflet valve.
  • Five of these implants were performed as part of the Israeli Pilot Study, led by Principal Investigator Ran Kornowski, MD.